semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Nutrition Immunology Able to provide written Informed Consent and follow verbal and written study directions in English Adult men and women between ages 40-80 years Body Mass Index (BMI) 25 to 40 kg/m2 (overweight, mild and moderate obesity) Must not be taking or be willing to stop taking cranberries or any products and supplements containing cranberries for seven days prior to the start of the study and for the duration of the study Must not be taking or be willing to stop taking supplements containing probiotics, or polyphenols and flavonoids (e.g., quercetin, anthocyanins, green tea extract) for seven days prior to the start of the study and for the duration of the study Able to maintain consistent diet and lifestyle habits throughout the study Healthy, noninstitutionalized participants or those with chronic but stable and well controlled medical conditions (i.e., hypertension controlled by a consistent dose of medication for a minimum of six months; chronic use of consistent dose of blood-thinning medication; diet-controlled Type II diabetes; statin controlled high blood cholesterol) may participate at the discretion of the primary investigator (PI) Willing and able to provide fasting blood samples and 24-hour urine samples Able to attend four scheduled visits at the AppState Human Performance Laboratory at the North Carolina Research Campus facility in Kannapolis, NC Willing to receive the 2020-21 seasonal influenza vaccination (with high-dose vaccinations given to those 65 years of age and older, as recommended by the Centers for Disease Control and Prevention)  Current active treatment for heart disease or cancer (excluding skin cancer), or medically complicated conditions (i.e., diabetes requiring insulin, uncontrolled high blood pressure), at the discretion of the primary investigator Inability to provide a venous blood sample or 24-hour urine sample Unable or unwilling to provide written informed consent for participation in study History of allergic reactions to cranberry juice or products containing cranberries Have already received the 2020-21 seasonal influenza vaccination
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cancer Covid19 Patients with proven COVID-19 and a diagnosis of cancer who are enrolled into any Tier of the Principal CCP-UK protocol  None in addition to those specified in the Principal CCP-UK protocol
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.5-2.0,  Vaccination subjects aged from 18 to 24 months old at the date of recruitment; 2. with informed consent signed by parent(s) or guardians; 3. parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions; 4. subjects have not been vaccinated with any type of Hepatitis A vaccines; 5. subjects have no Hepatitis A disease and contraindication of vaccination; 6. subjects did not receive any vaccines within 14 days; 7. before joining this trial, subjects must be qualified and passed their medical history and clinical examinations, and axillary's temperature must be ≤37℃  Subjects with history of allergy, convulsion, epilepsy, encephalopathy and psychosis or family history; 2. Allergic to any ingredient of vaccine or with allergy history to any vaccine; 3. Patients with immunodeficiency, in process of cancer treatment, immunosuppressive therapy (oral steroids) or HIV induced hypoimmunity, or in close contact with any family members who has congenital immune diseases; 4. Receive non-specific immunoglobulin within 1 month before recruitment; 5. Subjects with acute febrile diseases with body temperature > 37.0 ℃ or infectious diseases; 6. Subjects with a history of thrombocytopenia or other coagulation disorders that may be contraindicated for hypodermic injection; 7. With known or suspected concurrent diseases respiratory disease, acute infection or active chronic disease; 8. With severe cardiovascular diseases (Pulmonary heart disease, Pulmonary edema, hypertension cannot be controlled to normal range by drugs), liver and kidney diseases and diabetic complications; 9. Various infectious, suppurative or allergic dermatitis; 10. Other circumstances judged by investigators that are not suitable for this clinical trial
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Head and Neck Cancer Covid19 Any head and neck cancer patients (including salivary gland, thyroid, nasal and paranasal cancer with a COVID-19 diagnosis defined as any of the following Laboratory confirmed [Real Time Polymerase Chain Reaction (RT-PCR) technique] COVID-19 Suspected COVID-19 cases; diagnosed clinically based on symptoms (fever >37.5°, decrease of oximeter saturation of at least 5 %, cough, diarrhoea, otitis, dysgeusia, anosmia, myalgia, arthralgia, conjunctivitis and rhinorrhea and exposure to confirmed COVID-19 positive case (laboratory confirmation) Clinically diagnosed cases; suspected cases with lung imaging features consistent with coronavirus pneumonia Asymptomatic cases; diagnosed based on positive viral nucleic acid test results but without any COVID symptoms
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Obesity Weight Loss Eating Behavior overweight to obese (BMI 25-45 kg/m2) not currently engaged in exercise or weight loss activities free of any cardiac, pulmonary, or metabolic health conditions able to safely engage in exercise female participants must be premenopausal and not pregnant or nursing  Lost or gained over 5% of their current bodyweight in the previous 12 months taking any medications or dietary supplements which may influence energy expenditure or intake have not been diagnosed with an eating disorder, clinical depression, or an anxiety disorder engage in less than 150 minutes of moderate to vigorous physical activity per week (assessed via accelerometry at baseline)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rectal Cancer At least 18 years of age. Both men and women and members of all races and ethnic groups will be included. 2. Willing and able to provide written informed consent 3. Pathologic diagnosis of rectal adenocarcinoma 4. T3-4 and/or N+ disease 5. No prior treatment for rectal adenocarcinoma 6. Eastern Cooperative Group (ECOG) performance status of 0-2. 7. Laboratory values supporting acceptable organ and marrow function within 30 days of confirmation. Defined as follows WBC ≥ 3,000/mL ANC WBC ≥ 1,500/mL PLT ≥ 75,000/mL T Bili ≤ 1.5 x upper limit of normal (ULN) AST/ALT ≤ 2.5 x ULN Creatinine not above ULN, or creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. 8. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) starting with the first dose of study therapy through 90 days after the last dose of study drugs. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following 8.1 Has not undergone a hysterectomy or bilateral oophorectomy; or 8.2 Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)  Distant nodal disease (retroperitoneal nodes) including inguinal nodes, or any metastatic disease by CT or PET 2. Prior RT to the pelvis. 3. Uncontrolled comorbid illness or condition including an infection, congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness that would limit compliance with the study requirements. 4. Psychiatric illness/social situations that would limit consenting and compliance with study requirements. 5. Participants who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Adenocarcinoma Undergoing definitive or neoadjuvant CRT for histologically confirmed esophageal adenocarcinoma Have an ECOG performance status of 0-1 Have the ability to swallow and retain oral medication (Note: Placement of an enteric feeding tube after the patient has signed informed consent will not make them ineligible to participate in the study liquid formula propranolol will be made available) Participants of child-bearing potential must have a negative pregnancy test at study entry And then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure  Contraindications to the use of beta-blockers, e.g.; uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (New York Heart Association (NYHA) Grade III or IV), hypotension ( systolic blood pressure <100 mmHg), severe asthma or COPD, uncontrolled type I or type II diabetes mellitus (HbA1C >8.5 or fasting plasma glucose > 160 mg/dL at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current calcium channel blocker use (Non-dihydropyridines such as verapamil) or rhythm control agents such as digoxin and amiodarone. Patients with pacemakers will be excluded Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,symptomatic congestive heart failure, unstable angina pectoris, psychiatric illness/social situations that would limit compliance with study requirements, cardiac arrhythmia (atrial fibrillation/flutter), severe bradycardia (heart rate of <50 beats per minute or 1st/ 2nd /3rd degree heart block) Pregnant or nursing female participants Unwilling or unable to follow protocol requirements Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thoracic Cancer Abdominal Cancer Patients must be willing and capable to provide informed consent to participate in the protocol. 2. Patient with presumed pulmonary function capable of holding breath for at least 30 seconds later to be confirmed. 3. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and until study imaging is complete. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 3.1 A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 3.2 Patients must be compliant to all required pretreatment evaluations  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus 2. Patients are not compliant to all required pretreatment evaluations
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Trust Healthy adults over 18 years old  None
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Aged 18 or older If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use one effective method of contraception from 10 days prior to the antibody administration until 6 months after investigational product (IP) administration  Weight > 110 kg for groups S1 and S2 only History of prior positive SARS-CoV-2 RT-PCR or SARS-CoV-2 serology Active respiratory or non-respiratory symptoms consistent with COVID-19 Medically attended acute illness or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening Acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease [COPD], asthma exacerbations, or uncontrolled hypertension, as defined by a systolic blood pressure > 180 and/or diastolic blood pressure > 120, in the presence or absence of anti-hypertensive medications) in the past 6 months prior to screening Use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months Other clinically significant acute or chronic medical condition that in the opinion of the investigator would preclude participation Laboratory abnormalities in the parameters listed Absolute neutrophil count less than 1,500 K/mcL Hemoglobin less than 10.5 gm/dL if female; less than 11 gm/dL if male
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Complex Regional Pain Syndrome Type I for patients CRPS Type I (fulfilling Budapest for research) Suffering of CRPS in a distal limb (hand or foot) Age >18 years Pain lasting less than 6 months Good understanding of the French language for control Not suffering from chronic pain, including CRPS Age >18 years  for both group Known or suspected non-compliance, drug or alcohol abuse Inability to follow the procedures of the study, e.g. due to language problems, severe psychological disorders, dementia, etc For blood sample: diabetes and history of hepatitis B, C, D or HIV infection
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Healthy Chronic Disease Both sexes Age >18 years Signed informed consent for the donation / sample storage in the Biological Bank  for healthy subjects: all those who have shown any symptoms, albeit mild, in the 28 days prior to the donation for patients: who have not signed the informed consent for the conservation of their samples in the Biological Bank
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID-19 SARS-CoV-2 Male or female patients aged 18 years and older infected with the SARS-CoV-2 infection Patients with COVID-19 symptoms and have a positive PCR test result Patients in a stable clinical condition and basically in an outpatient condition Patients who sign the informed consent  Patients with a partial oxygen pressure < 90% and who have required hospitalization Patients who have required intensive care Any condition which, in the opinion of the Principal Investigator, would prevent full participation in and compliance with the trial protocol Patients who have been involved in any other interventional studies Patients with uncontrolled Type I or Type II diabetes mellitus (DM) Patients with severe liver failure (Child Pugh score ≥ C, AST> 5 times the upper limit of normal (ULN) Patients with severe renal failure (GFR ≤30 mL/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy Patients with serious cardiac problems such as heart failure Patients with hypersensitivity to montelukast or other drugs in the study Patients with rare hereditary problems of galactose / fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-64.0,  Menopause We will all menopausal health-care providers working in CAD of Women's Health and Pediatric CAD UMC, NCCR, and RDC, Nur-Sultan Kazakhstan. In order to get the highest possible response rate as well as evaluate the non-response bias, there is a need to follow-up to those who did not responded  Women with serious health problems, such as severe chronic diseases, including psychological/psychiatric comorbidities, and use of specific drugs for them, will not be included in the study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaccination Hospitalization in one of the departments participating in the study At risk of pneumococcal infection according to HCSP recommendations (1) Negative pneumococcal vaccination status Adult patient (≥18 years old)  Under safeguard of justice Unable to receive informed information Patient having objected to the use of their data